Welcome to our dedicated page for Summit Therapeutics news (Ticker: SMMT), a resource for investors and traders seeking the latest updates and insights on Summit Therapeutics stock.
Summit Therapeutics Inc. (NASDAQ: SMMT) is a biopharmaceutical oncology company whose news flow is closely tied to the development of its lead investigational therapy, ivonescimab (SMT112 in Summit’s territories). Ivonescimab is described by the company as a potential first-in-class bispecific antibody targeting PD-1 and VEGF in a single molecule, and it is being evaluated in multiple Phase III clinical trials in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
News about Summit frequently covers clinical milestones for ivonescimab, including updates from the global Phase III HARMONi trial in EGFR-mutated NSCLC after third-generation EGFR TKI therapy, as well as HARMONi-3 and HARMONi-7 in first-line metastatic NSCLC and HARMONi-GI3 in first-line unresectable metastatic CRC. Company announcements have highlighted progression-free survival and overall survival data, hazard ratios, response rates, and safety profiles, along with presentations at major conferences such as the World Conference on Lung Cancer, SITC, and ESMO.
Investors following SMMT news will also see regulatory and corporate updates, including Summit’s submission of a Biologics License Application to the U.S. FDA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC, Fast Track designation for the HARMONi setting, and summaries of Akeso’s HARMONi-A trial in China, which demonstrated a statistically significant overall survival benefit for ivonescimab plus chemotherapy versus chemotherapy alone.
Additional news items cover financing activities such as private placements and at-the-market offerings, inducement stock option grants under Nasdaq Listing Rule 5635(c)(4), and collaboration announcements. Notably, Summit has reported a clinical trial collaboration with GSK plc to evaluate ivonescimab in combination with GSK’s investigational B7-H3-targeting antibody-drug conjugate, risvutatug rezetecan (GSK’227), across multiple solid tumor settings including small cell lung cancer.
For readers tracking SMMT, the news stream provides insight into Summit’s late-stage oncology pipeline, regulatory interactions, capital-raising efforts, and partnerships that shape the company’s development path.
Summit Therapeutics (NASDAQ: SMMT) presented an ePoster at IDWeek 2021 highlighting the novel mechanism of action of ridinilazole, its investigational antibiotic for Clostridioides difficile infections. The Phase III trial, Ri-CoDIFy, aims to demonstrate ridinilazole's superiority over vancomycin. The ePoster reveals evidence from high-resolution imaging of ridinilazole binding to bacterial DNA, underscoring its potential as the first new antibiotic mechanism approved in over a decade. Ridinilazole could play a significant role in addressing antibiotic resistance.
Summit Therapeutics Inc. (NASDAQ: SMMT) reported its Q2 2021 financial results, revealing cash and cash equivalents of $103.4 million, up from $66.4 million at year-end 2020. The company raised $75 million via a Rights Offering, primarily used to repay previous debt. However, net losses increased to $24.4 million for Q2 2021 from $15.3 million in Q2 2020. Notably, BARDA provided support for clinical trials with funding of up to $72.5 million. The company also advanced its antibiotic SMT-738 and expanded its pipeline into oncology and microbiome health.
On August 11, 2021, Summit Therapeutics (NASDAQ: SMMT) announced its decision to combine two ongoing Phase III clinical trials evaluating ridinilazole against vancomycin for Clostridioides difficile infections. Current enrollment stands at 753 patients, allowing for a prospective planned analysis. Ridinilazole aims to demonstrate superiority in sustained clinical response over vancomycin, although it remains unapproved. The company’s Phase II data highlighted ridinilazole's minimal impact on the gut microbiome. The trials are funded in part by BARDA, reflecting confidence in their potential outcomes.
Summit Therapeutics showcased three notable ePosters at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) focused on its investigational drug, ridinilazole, for treating Clostridioides difficile infections. Key findings include ridinilazole's ability to preserve gut microbiota without increasing antibiotic resistance, and its novel mechanism of action targeting C. difficile DNA. Amid two pivotal Phase III trials, these results reinforce ridinilazole's potential as a first-line treatment, minimizing disease recurrence and aligning with regulatory efforts for its approval.
Summit Therapeutics (NASDAQ: SMMT) announced that its scientific team will present significant research at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) from July 9-12, 2021. Highlights include a Top Rated ePoster on the impact of the antibiotic Ridinilazole on gut microbiota. Ridinilazole is in Phase III trials aimed at treating and preventing recurrence of Clostridioides difficile infection (CDI), a serious illness affecting over 500,000 annual cases in the U.S. The company aims to provide effective therapies with minimal side effects.
Summit Therapeutics Inc. (NASDAQ: SMMT) will join the Russell 3000® Index after the annual reconstitution on June 28, 2021. This addition, determined by market capitalization, signifies recognition of the company's progress in addressing unmet medical needs. The Russell 3000® Index, encompassing 4,000 large U.S. stocks, facilitates investment strategies for managers, with over $10.6 trillion benchmarks tied to it. Summit Therapeutics aims to lead in treatments for infectious diseases, focusing on novel antibiotics aligned with the human microbiome.
Summit Therapeutics Inc. (NASDAQ: SMMT) is set to hold its virtual Annual Shareholders’ Meeting on June 16, 2021, at 1:00 pm ET. Shareholders and interested parties are invited to attend through a provided online link. The company's innovative Discuva Platform aims to advance treatments for infectious diseases, focusing on Clostridioides difficile infections. Summit's lead candidate, ridinilazole, is currently in pivotal Phase 3 trials, while SMT-738 is in the IND-enabling phase for multidrug-resistant infections. Regulatory approvals are essential for commercialization.
Summit Therapeutics (NASDAQ: SMMT) has selected SMT026738, a new preclinical candidate targeting multidrug-resistant infections, particularly carbapenem-resistant Enterobacteriaceae (CRE). The company received an initial award of up to $4.1 million from CARB-X to advance SMT-738 through preclinical and Phase 1a trials, with potential additional funding of $3.7 million based on milestones. SMT-738 employs a novel mechanism using LolCDE, targeting pathogens like Escherichia coli and Klebsiella pneumoniae, offering hope against infections with limited treatment options due to antibiotic resistance.
Summit Therapeutics Inc. (NASDAQ: SMMT) reported its Q1 2021 financial results, highlighting significant developments in its clinical trials and financial standing. The company has enrolled 652 patients in its ridinilazole Phase 3 trials, with a goal of 1,360. Financially, cash and cash equivalents rose to $102.2 million, up from $66.4 million at the end of 2020, bolstered by a $75 million Rights Offering. However, the company posted a net loss of $17.5 million for Q1 2021, significantly higher than the $6.1 million loss in Q1 2020.
Summit Therapeutics Inc. (NASDAQ: SMMT) announced the successful closing of its rights offering, raising $75 million from the sale of 14,312,976 shares at $5.24 each. The offering incurred approximately $200,000 in expenses, resulting in net proceeds of $74.8 million. Following this issuance, the total shares outstanding is 97,244,567. CEO Mr. Duggan emphasized the offering allowed all stockholders to participate based on their ownership. Unexercised subscription rights expired on May 10, 2021.